{
    "nctId": "NCT00436917",
    "briefTitle": "Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer",
    "officialTitle": "Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Osteoporosis",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of localized breast cancer\n\n  * Stage I-IIIA disease\n  * Adequately treated breast cancer\n\n    * No clinical or radiological evidence of recurrent or metastatic disease\n* Baseline total lumbar spine or femoral neck bone mineral density T-score \\< -2.0 standard deviation (e.g., a patient with a T score of -2.1 is eligible)\n* Hormone-receptor status:\n\n  * Estrogen receptor and/or progesterone receptor-positive breast cancer\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Postmenopausal, defined by 1 of the following criteria:\n\n  * Age \\> 55 years with cessation of menses\n  * Age \u2264 55 years with spontaneous cessation of menses for \\> 1 year\n  * Age \u2264 55 years with spontaneous cessation of menses for \u2264 1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND has postmenopausal estradiol levels\n  * Bilateral oophorectomy\n* ECOG performance status 0-2\n* Life expectancy \u2265 5 years\n* WBC \u2265 3,000/mm\u00b3 OR granulocyte count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Alkaline phosphatase \u2264 3 times upper limit of normal (ULN)\n* AST \u2264 3 times ULN\n* Creatinine \\< 2.0 mg/dL\n* Creatinine clearance \u2265 45 mL/min\n* No hypercalcemia (i.e., calcium level \\> 1 mg/dL above ULN) OR hypocalcemia (i.e., calcium level \\> 0.5 mg/dL below lower limit of normal) within the past 6 months\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No other nonmalignant systemic diseases, including any of the following:\n\n  * Uncontrolled infection\n  * Uncontrolled diabetes mellitus\n  * Uncontrolled thyroid dysfunction\n  * Disease affecting bone metabolism (hyperparathyroidism, hypercortisolism, Paget's disease, osteogenesis imperfecta)\n  * Malabsorption syndrome\n* No uncontrolled seizure disorders associated with falls\n* No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or vitamin D\n* No concurrent active dental problems, including any of the following:\n\n  * Infection of the teeth or jawbone (maxillary or mandibular)\n  * Dental or fixture trauma\n  * Prior or current diagnosis of osteonecrosis of the jaw\n  * Exposed bone in the mouth\n  * Slow healing after dental procedures\n* No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following:\n\n  * History of surgery at the lumbosacral spine, with or without implantable devices\n  * Scoliosis with a Cobb angle \\> 15 degrees at the lumbar spine\n  * Immobility, hyperostosis, or sclerotic changes at the lumbar spine, or evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan\n  * Disease of the spine that would preclude the proper acquisition of a lumbar spine DXA\n* No condition that would preclude study follow-up or compliance\n* No psychiatric illness that would preclude giving informed consent\n\nPRIOR CONCURRENT THERAPY:\n\n* More than 3 weeks since prior and no other concurrent oral bisphosphonates\n* No prior intravenous bisphosphonates\n* No prior aromatase inhibitor therapy\n* More than 6 months since prior anabolic steroids or growth hormone\n* More than 2 weeks since prior and no concurrent inhibitor of osteoclastic bone resorption (e.g., calcitonin, mithramycin, or gallium nitrate)\n* More than 30 days since prior systemic investigational drug and/or device\n* More than 7 days since prior topical investigational drug\n* More than 6 weeks since prior and no concurrent dental or jaw surgery (e.g., extraction, implants)\n* Concurrent short-term corticosteroid therapy allowed\n* No concurrent sodium fluoride, parathyroid hormone, or tibolone\n* No other concurrent investigational drug or device",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}